Rathi VK, et al. - Since more than 17 million individuals in the US have obstructive sleep apnea, a condition related to sequelae like daytime somnolence, motor vehicle crashes, and cardiovascular disease, researchers studied the use and cost of a hypoglossal nerve stimulator device for obstructive sleep apnea between 2015 and 2018. Continuous positive airway pressure systems are the first-line therapy for obstructive sleep apnea, although patient non-compliance often limits the efficacy of such therapy. Data reported that there are second-line treatments (eg, oral appliances and palatal surgery), but there is limited support for such alternatives in the available evidence.